Despite two decades of intensified research to understand and cure tuberculosis disease,
biological uncertainties remain and hamper progress. However, owing to collaborative …

Insufficient development of new antibiotics and the rising resistance of bacteria to those that
we have are putting the world at risk of losing the most widely curative class of medicines …

Combination therapy has shown an obvious efficacy on complex diseases and can greatly
reduce the development of drug resistance. However, even with high-throughput screens …

Lengthy multidrug chemotherapy is required to achieve a durable cure in tuberculosis.
However, we lack well-validated, high-throughput in vitro models that predict animal …

Current chemotherapy against Mycobacterium tuberculosis (Mtb), an important human
pathogen, requires a multidrug regimen lasting several months. While efforts have been …

Introduction Tuberculosis requires lengthy multi-drug therapy. Mycobacterium tuberculosis
occupies different tissue compartments during infection, making drug access and …

Tuberculosis (TB) remains as one of the world's deadliest infectious diseases despite the
use of standardized antibiotic therapies. Recommended therapy for drug-susceptible TB is …

New techniques for systematic profiling of small-molecule effects can enhance traditional
growth inhibition screens for antibiotic discovery and change how we search for new …

Tuberculosis (TB) continues to be one of the deadliest infectious diseases in the world,
causing~ 1.5 million deaths every year. The World Health Organization initiated an End TB …

Combination therapies can overcome antimicrobial resistance (AMR) and repurpose
existing drugs. However, the large combinatorial space to explore presents a daunting …